EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Video and podcast roundups

How should a clinic turn the watchlist into a procurement decision?

Dose Diligence research deskSection 07 · Page 7 of 9Last updated 17 Nov 2026

Assign an output to each recording. The following is our proposed workshop, not a claim that any episode supplies a complete procurement method.

WorkstreamRecording inputsRequired buyer outputSuggested decision boundary
Clinical and route reviewEndocrine Society; JAMA; Frier Levitt; current FDA materialExact product and arrangement, clinical responsibilities, unresolved legal questionsDo not begin price-weighted ranking while material eligibility questions remain unresolved
Supplier quality and provenanceNABP API/testing and counterfeit sessionsFacility-specific evidence register and exception processDo not substitute a presentation, certificate logo or registration claim for the underlying evidence
Multi-state readinessNABP telemedicine sessionState-by-state responsibility and evidence matrixDo not launch a state solely on a national-coverage claim
Branded accessIPC; ASHPPatient journey, eligibility checks, payment and support ownershipDo not assume manufacturer-linked access is clinic wholesale purchasing
EconomicsAH104Matched quotation workbook, separated by payerDo not count patient savings as clinic margin
Continuity and implementationPharmaSourcePilot plan, exception tests, reporting and exit responsibilitiesDo not equate a successful initial order with demonstrated ongoing capacity

For a LillyDirect versus pharmacy-partner or NovoCare access comparison, reopen the manufacturer’s operational material rather than copying a podcast’s historical offer. Lilly describes a patient-access experience involving third-party dispensing pharmacies; NovoCare maintains a provider-facing home-delivery page. Neither page should be treated as a negotiated clinic-stock quotation. LillyDirect FAQ; NovoCare provider delivery information.

For the cost workbook, we recommend separate lines for medicine, dispensing, delivery, platform charges, failed fulfilment, wastage and internal handling. Define a successfully fulfilled patient-month explicitly—for example, the agreed supply arriving within the agreed window—and keep that operational measure separate from clinical benefit. This is a proposed comparison framework, not an industry benchmark established by these recordings.

What should the team request after listening?

  • Exact contracting and dispensing entities, facility locations and intended products.
  • Evidence supporting the proposed route, reviewed by the appropriate clinical and legal owners.
  • Destination-state permissions and operational acceptance of the proposed prescriptions.
  • A matched quotation showing introductory and ongoing terms, included services and who pays.
  • Order-status reporting, escalation ownership and handling of unsuccessful orders.
  • Quality, shipping, recall and complaint documentation appropriate to the arrangement.
  • A controlled implementation plan and a documented patient-transition process.
  • Counsel review of minimum commitments, change-in-law provisions, termination and transition assistance.
Explore the table row by row

A working view of the research

Clinical and route review

Recording inputs
Endocrine Society; JAMA; Frier Levitt; current FDA material
Required buyer output
Exact product and arrangement, clinical responsibilities, unresolved legal questions
Suggested decision boundary
Do not begin price-weighted ranking while material eligibility questions remain unresolved

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
  2. novocare.com · Source 2 ↗https://www.novocare.com/hcp/delivery.html
Section sources →